Related Experiment Video
Updated: Oct 10, 2025

A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials
Ankit Patel1, Joseph Skitzki1,2
1Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Abstract:
Adjuvant systemic therapy for cutaneous melanoma has experienced practice-changing shifts over the last decade. The successful results of immunotherapies and targeted therapies in the metastatic setting have allowed for investigative trials of the same therapies in the adjuvant and now neoadjuvant setting, with the potential for improved clinical outcomes in patients with high risk resected Stage III and IV melanoma.
Insights
Systemic therapies, including immunotherapy and targeted treatments, are revolutionizing adjuvant and neoadjuvant care for high-risk cutaneous melanoma. These advancements offer potential for better outcomes in patients with resected Stage III and IV disease.
Area of Science:
- Oncology
- Dermatology
- Clinical Trials
Background:
- Cutaneous melanoma treatment has evolved significantly.
- Adjuvant systemic therapy is a critical area of research.
Purpose of the Study:
- To review the shifts in adjuvant systemic therapy for cutaneous melanoma.
- To explore the application of immunotherapies and targeted therapies in the adjuvant and neoadjuvant settings.
Main Methods:
- Review of recent clinical trial data.
- Analysis of therapeutic successes in metastatic melanoma.
- Investigation of neoadjuvant and adjuvant treatment strategies.
Main Results:
- Immunotherapies and targeted therapies show promise.
- Successful translation from metastatic to earlier settings (adjuvant/neoadjuvant).
Conclusions:
- High-risk resected Stage III and IV melanoma patients may benefit from novel systemic therapies.
- Ongoing research aims to improve clinical outcomes through early intervention.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy
Cancer Survival Analysis

